The latest update is out from CSPC Pharmaceutical Group ( (HK:1093) ).
CSPC Pharmaceutical Group has announced that its antibody-drug conjugate, SYS6040, has received approval from China’s National Medical Products Administration to commence clinical trials for advanced solid tumors. This development highlights the product’s promising anti-tumor effects and potential clinical value, with several patent applications already submitted both in China and internationally.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group is a company in the pharmaceutical industry, focusing on the development of therapeutic biological products, including monoclonal antibody-drug conjugates, with a market focus on innovative cancer treatments.
YTD Price Performance: 9.49%
Average Trading Volume: 6,363
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $7.4B
Find detailed analytics on 1093 stock on TipRanks’ Stock Analysis page.